Pharmaq

At exit, PHARMAQ was one of the world’s leading aquatic health group manufacturing vaccines and therapeutic products for the aquaculture industry. See how our backing supported the company’s international growth and new product development plans…

Norway

Realised

Together we achieved

  • Strengthening of PHARMAQ’s position as a global leader in health products focused on the aquaculture industry
  • Expanding into emerging markets and becoming a viable alternative to antibiotics usage in food production, by launching the company’s first vaccines focused on pangasius in Vietnam and tilapia in Central America
  • Extending the product offering in the core salmonid market to provide protection against devastating diseases that are currently left unaddressed
  • Sale to a trade buyer

This was accomplished by

  • Partnering with the founding management team to make significant investments in strengthening the team to achieve the international growth agenda
  • Increasing R&D investment, allowing PHARMAQ to significantly expand and enhance its product offering for its core salmonid markets, as well as innovate new product lines catering to new species and geographies to better serve the rapidly developing aquaculture industry
  • Establishing dialogues with leading research institutions and regulatory bodies in key future growth markets ensuring PHARMAQ ready to capitalise on the opportunity from future industrialisation of aquaculture in emerging markets

www.pharmaq.com

The metrics

Trade sale

Exit type

$765m

Exit value